𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

✍ Scribed by Alan Pollack; Gunar K Zagars; George Starkschall; John A Antolak; J.Jack Lee; Eugene Huang; Andrew C von Eschenbach; Deborah A Kuban; Isaac Rosen

Book ID
108434777
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
132 KB
Volume
53
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Increasing dose intensity of cisplatin-e
Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma : A Phase III randomized trial of the Spanish lung cancer group
✍ Albert Font; Alfredo J. Moyano; Jose M. Puerto; Alejandro Tres; Carlos Garcia-Gi πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 97 KB πŸ‘ 2 views

## Background: The authors designed this randomized, controlled trial to assess whether dose intensification of a cisplatin-etoposide combination (pe), achieved by shortening the interval between chemotherapy cycles, would improve response rate and survival. the maximum tolerated dose of pe was adm

The trifunctional antibody catumaxomab f
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
✍ Markus M. Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O. Kol πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 559 KB

## Abstract Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody catumaxomab (anti‐epithelial cell‐adhesion molecule x anti‐CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.) treatment of malignant ascite